NanoViricides is trading at $1.37, a change of -5.19%, with biotech-sector pressure the clearest available context.
- XBI fell 2.50% in the session, while broader markets were higher.
- NanoViricides announced a conference presentation for October 7; no evidence links it to the decline.
- A report said shares rose 13% on October 5 amid broader outbreak-related trading, but that rally does not establish the cause of this decline.